© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Rebamipide stands as an established raw material in the pharmaceutical sector that has contributed to research, formulation, and therapy, predominantly for its use in treating gastric mucosal disorders. As a chemical compound, Rebamipide falls under the molecular formula C19H15ClN2O4, with a precise molecular weight of 370.79 g/mol. Researchers and manufacturers alike value its consistency and the extensive documentation supporting its physical and chemical identity. Its structure, marked by the presence of both benzamide and quinolone groups, creates a stable profile that offers versatility in downstream applications.
Rebamipide appears typically as a white to off-white crystalline powder, sometimes showing a slightly pearlescent quality depending on crystal size and purity. This physical state allows for direct handling as a solid or powder, which simplifies measuring and mixing in laboratory and production environments. Specialists working with bulk chemicals notice its solid flakes and crystal shapes, finding these characteristics helpful for the preparation of consistent solutions and suspensions. The compound boasts a density near 1.45 g/cm³, a detail critical when configuring formulation equipment or calculating bulk storage volumes. Rebamipide’s solubility remains limited in water, but it dissolves in organic solvents, including dimethyl sulfoxide and ethanol, which impacts the approach toward product development and storage.
Pharmaceutical-grade Rebamipide products require a high level of purity, often exceeding 99%. Testing confirms this through methods such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR), ensuring that each batch meets precise standards for use as an active pharmaceutical ingredient. The material flows freely in powder form but also gets processed into tablets, pearls, and possibly even liquid solutions by downstream companies. Manufacturers print specification sheets listing lot numbers, moisture content (usually below 0.5%), and retesting intervals, all critical details for maintaining compliance with regulatory expectations. Products use the Harmonized System Code (HS Code) 2933990099 under trade regulations governing pharmaceuticals containing nitrogen. Safe handling emerges as a clear focus—each drum or sachet arrives marked with chemical and hazard labels, including notes about the low-level harmful nature of dust or accidental ingestion.
No one approaches chemicals like Rebamipide without a full review of safety data. Occupational exposure guidelines and hazard statements promote safety across research and manufacturing. Inhalation of powder can cause respiratory irritation, so full-face respirators or appropriate masks see regular use, and workspaces feature local exhaust ventilation. The solid form keeps spillage risk relatively low, but labs maintain spill kits and protocols to deal with accidental release. Rebamipide classifies as a non-flammable solid under standard shipping laws, so it travels as a general cargo unless blended with solvents that change its risk profile. Material Safety Data Sheets (MSDS) advise on inert packaging, tightly sealed containers, and storage away from incompatible chemicals. Long-term exposure tests have shown RT50 and LD50 values that label the compound as low acute toxicity, though precaution remains standard procedure.
Examining Rebamipide’s chemical structure gives insight into its reactivity and potential for synthetic modification. The presence of carbonyl and amide groups, combined with aromatic rings and a chlorine substituent, influences both its pharmacological action and underlying stability. Medicinal chemists find this an attractive platform for analog development or structural analysis, particularly given its proven record in protecting epithelial tissue. Rebamipide’s inclusion in raw material inventories signals a commitment to high-quality antiulcerative agents, with further applications possible if future studies uncover additional therapeutic targets. Formulators value the crystalline solid as an easy-to-weigh bulk material that accommodates direct mixing, coating, tablet pressing, and controlled dissolution studies.
Pharmaceutical companies keep Rebamipide raw material on-hand due to its certification as an API and its solid-powder state, which aids in efficient manufacturing workflows. The compound progresses from material quarantine upon arrival to cleanroom-grade blending and processing, always tracked under digital quality management systems. The raw material label reminds users of its importance; each lot must pass the threshold for purity, microbial load, and absence of hazardous contaminants. Sometimes, Rebamipide appears in research material listings, flagged for synthetic chemistry or positive tissue response models. Over time, the industry has developed robust supply chain solutions to meet demand, while also enforcing compliance with international chemical trading rules.
Years of working with chemical raw materials urge attention not just on immediate hazards but on wider environmental outcomes. Rebamipide’s chemical nature means waste management plans handle expired or spilled materials as pharmaceutical waste, keeping them from landfill or untreated water. Governments regulate transportation, shipment, and documentation with oversight under customs codes and hazardous goods regulations even if immediate danger remains low. Industry players conduct impact reviews, especially concerning large-scale manufacture, storage, and shipment, and often invest in training for responsible handling and reporting of any adverse events related to use or exposure.
Experience in sourcing and handling raw pharmaceutical ingredients like Rebamipide suggests improvement always starts with clearer labeling, thorough training, and robust supply chain documentation. Reducing dust generation during processing grows easier with improved enclosure design and vacuum-assisted hoppers. At the same time, research teams can look at solvent alternatives for dissolution to minimize potential employee exposure to both Rebamipide and the organic chemicals often paired with it. Enhanced collaboration along the supply chain—from raw material provider to finished product plant—brings fresh approaches to tracking, accountability, and continuous improvement. Compliance departments see routine audits as a tool, not a burden, blending product stewardship with risk management. When a company treats Rebamipide as more than a commodity, it invests in smarter, safer, and more reliable access to life-changing medical compounds.
